

University of Groningen

Early detection of left ventricular remodeling

Hendriks, Tom

DOI:
[10.33612/diss.144600179](https://doi.org/10.33612/diss.144600179)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Hendriks, T. (2020). *Early detection of left ventricular remodeling*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.144600179>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chapter 3.


Effect of systolic blood pressure on
left ventricular structure and function: a
Mendelian randomization study

Tom Hendriks, M. Abdullah Said, Lara M.A. Janssen, M. Yldau van
der Ende, Dirk J. van Veldhuisen, Niek Verweij, Pim van der Harst

Hypertension. 2019;74(4):826-832.

ABSTRACT

We aimed to estimate the effects of a lifelong exposure to high SBP on left ventricular (LV) structure and function using Mendelian randomization. A total of 5,596 participants of the UK Biobank were included for whom cardiovascular magnetic resonance imaging (CMR) and genetic data were available. Major exclusion criteria included non-Caucasian ethnicity, major cardiovascular disease and BMI >30 or <18.5 kg/m². A genetic risk score to estimate genetically predicted SBP (gSBP) was constructed based on 107 previously established genetic variants. Manual CMR post-processing analyses were performed in 300 individuals at the extremes of gSBP (150 highest and lowest). Multivariable linear regression analyses of imaging biomarkers were performed, using gSBP as continuous independent variable. All analyses except myocardial strain were validated using previously derived imaging parameters in 2,530 subjects. The mean (SD) age of the study population was 62 (7) years and 52% of subjects were female. Corrected for age, sex, and body surface area, each 10 mmHg increase in gSBP was significantly ($P<0.0056$) associated with 4.01 (SE 1.28, $P=0.002$) grams increase in LV mass and with 2.80 (SE 0.97, $P=0.004$) percent increase in LV global radial strain. In the validation cohort, after correction for age, sex, and body surface area, each 10 mmHg increase in gSBP was associated with 5.27 (SE 1.50, $P<0.001$) grams increase in LV mass. Our study provides a novel line of evidence for a causal relationship between SBP and increased LV mass, and with increased LV global radial strain.



INTRODUCTION

Hypertension, traditionally defined as a systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg (1), and in 2017 redefined by the American Heart Association as a SBP ≥ 130 mmHg or DBP ≥ 80 mmHg (2), is a highly prevalent condition which plays an essential role in the etiologies of a wide range of cardiovascular diseases. In 2011-2014, the prevalence of hypertension in adults in the United States, according to the most recent definition, was estimated at 45.6% (3). When left untreated, a high blood pressure can lead to adverse left ventricular (LV) remodeling such as LV hypertrophy (LVH), which is associated with an increased incidence of heart failure and cardiovascular death (4-6). However, high blood pressure tends to cluster with other cardiovascular risk factors such as obesity and smoking, making it difficult to identify independent effects of blood pressure on the structure and function of heart. Genome-wide association studies have successfully identified genetic variants associated with blood pressure and hypertension (7-12). Individuals with more blood pressure-raising alleles, and therefore a higher genetic risk of developing hypertension, are at higher risk of developing coronary artery disease (13). It is yet unknown whether the relationship between increased blood pressure and adverse LV remodeling is of a causal nature. This study aimed to assess the causality of previously established associations between increased blood pressure and adverse LV remodeling, by determining the effect of genetically predicted SBP (gSBP) on LV structure and function.

METHODS

The data for this study is publicly available to registered investigators of the UK Biobank. Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the UK Biobank at <https://www.ukbiobank.ac.uk/>. Analyses were performed using individuals included in the cardiovascular magnetic resonance imaging (CMR) substudy of the UK Biobank resource (14) with available short axis cine images and genetic data (N=5,596) (15). Townsend deprivation index (TDI), an area-based proxy for socio-economic status, was calculated by the UK Biobank at baseline visit and inverse rank normalized. Body surface area (BSA) was calculated as proposed by DuBois and DuBois (16). Blood pressure was calculated as the mean value of two automated or manual measurements, and was adjusted for the use of an automated device using a previously described algorithm (17). Physical activity was calculated using answers from touchscreen questions, and classified into moderate-intensity (3.0-6.0 metabolic

equivalents, METs) or vigorous-intensity physical activity (>6.0 METs) (18). Medical history was defined using self-reported answers from questionnaires and hospital episode statistics. Several diseases were additionally defined by medication use: hypertension (oral beta blocker, ACE inhibitor, angiotensin II receptor antagonist, thiazide diuretic and/or calcium channel blocker), hyperlipidemia (cholesterol-lowering medication), and diabetes mellitus (oral antidiabetic and/or insulin). Subjects with unavailable SBP measurements ($N=40$), unavailable height measurements ($N=6$), non-Caucasian ethnicity ($N=162$), $BMI <18.5$ or >30 kg/m² ($N=1,078$), a medical history of coronary artery disease, heart failure, cardiomyopathy, cardiac surgery, percutaneous cardiac intervention, peri-/myocarditis, cardiac arrhythmia, heart valve disease, pulmonary hypertension, use of oral anticoagulants, non-coronary arterial disease, stroke, thromboembolism, malignancy, and/or renal failure ($N=1,101$) were excluded from analyses. Non-Caucasian ethnicity (3% of the study population) was excluded to improve the homogeneity of the study population and because effects of genetic variants might vary across ethnicities. Subjects with major cardiovascular disease, active malignancy, renal failure, and obesity were excluded, because their effect on LV structure and function has been reported and might dilute the observed effect of gSBP. After applying exclusion criteria, 3,209 subjects remained in the study population.


Genotyping in the UK Biobank

The genotyping and imputation process in the UK Biobank has been described in more detail previously (15). Briefly, individuals were genotyped using either the custom UK Biobank Axiom array that included 820,967 genetic variants ($N=452,713$; here $N=2,906$) or the UK Biobank Lung Exome Variant Evaluation Axiom array that included 807,411 genetic variants ($N=49,949$; here $N=303$). Both arrays have insertion and deletion markers and have $>95\%$ common content. UK Biobank provided imputed genotype data based on merged UK10K and 1000 Genomes phase 3 panels.

Mendelian randomization

A genetic risk score (GRS) for SBP was constructed in all remaining participants to quantify gSBP using variants reported in literature. When this study was designed in June 2017, we identified 128 previously discovered genetic variants for SBP in previously reported genome-wide association studies (7-12), of which 126 were available in the UK Biobank, as listed in *Supplementary Table S1* and described in Said et al. (19). Because some studies reported multiple correlated variants in the same genetic locus, the linkage disequilibrium clumping procedure (at $R^2 < 0.01$) implemented in PLINK version 1.9 was used to select 107 independent SNPs, based on the lowest reported P-value. For these 107 genetic variants, we used reported effect sizes that were estimated in the largest sample size that did not include UK Biobank data, for example from the replication sample, to prevent circular inference and avoid over-estimation of the effect.

Figure 1. Association between gSBP and pSBP




Presented is a local polynomial smooth plot with 95% confidence interval, using the Epanechnikov kernel function and 50 smoothing points.

The GRS was constructed by summing the number of blood pressure-raising alleles (0, 1 or 2) for each individual after multiplying the alleles with the reported effect size of the genetic variant on SBP. *Figure 1* highlights the association between gSBP and phenotypic SBP (pSBP). In order to optimize the statistical power of the study, participants with the lowest and highest GRS values were selected for further CMR post-processing analyses, and were allocated to a low gSBP (N=150, 4.8% of study population) and high gSBP (N=150) group respectively. Image quality was assessed by observers blinded to study group, based on presence of artifacts, axis alignment and short axis coverage of LV. In case of insufficient image quality (N=15), subjects were excluded from analyses and replaced by subjects with subsequent highest or lowest GRS values in order to keep 150 subjects in both groups. GRS thresholds used to select the final study groups were <4.45 mmHg for the low gSBP group and >13.16 mmHg for the high gSBP group (*Figure 2*).

Cardiovascular magnetic resonance imaging post-processing

Post-processing analyses were performed by two experienced observers using cvi42 version 5.6.4 (Circle Cardiovascular Imaging, Calgary, Alberta, Canada), blinded to patient characteristics and study group. Epi- and endocardial LV contours were traced at end-diastolic and end-systolic phases according to contemporary guidelines in short-axis cine series to determine LV mass, LV end-diastolic volume (LVEDV), and LV end-systolic volume (LVESV) (20). Papillary muscles and trabeculae were included in the LV cavity. LV mass was determined at the end-diastolic phase. LV mass to volume ratio was calculated by dividing LV mass by LVEDV. Myocardial strain measurements were done using the cvi42 tissue tracking plugin (*Supplementary Figure S1*). Peak global circumferential and radial strain were measured in the short-axis cine series. Peak global longitudinal strain was measured by manually tracing endo- and epicardial contours at end-diastolic phase in three long axis cine series (2-chamber view, 3-chamber view, 4-chamber view), and calculating mean values. In case of insufficient quality of 4-chamber view series (N=9), 3-chamber view series (N=6), or 2-chamber view series (N=2) due to severe artifacts or very poor

Figure 2. Distribution of genetic risk score for systolic blood pressure in UK Biobank population after initial exclusion criteria (N=3,209)



axis alignment, series were excluded and mean values of the remaining measurements were used.

Validation cohort

To validate our results observed in a population with extreme GRS values, we used imaging parameters previously derived by Petersen et al. (21, 22), which were available in 2,530 subjects out of 3,209 subjects that remained in the study after applying in- and exclusion criteria and excluding our study population. LV myocardial strain measurements were not available and could not be validated.

Statistical analyses

Baseline characteristics of the study population are presented by study group. Continuous variables are presented as mean with standard deviation (SD) when normally distributed, and as median with interquartile range (IQR) in case of a non-normal distribution. Categorical and dichotomous variables are presented as number with percentage. Differences between groups were compared using ANOVA for normally distributed continuous variables, Wilcoxon rank-sum for non-normally distributed continuous variables, and Pearson's chi-squared for categorical and dichotomous variables.

To determine intra- and interobserver variability in imaging parameters, intraclass correlation coefficients for derived imaging biomarkers were calculated in a subset of the study population in which post-processing analyses were repeated. Linear regression analyses were performed on derived imaging biomarkers using GRS (as an estimate of gSBP) as a continuous independent variable, adjusted for genotyping chip used and the first five principal components (to adjust for population structure). First, basic univariate linear regression analyses were performed. Next, multivariable linear regression analyses were performed to correct for the effects of possible confounders, using two models of covariates. A basic model of covariates (Model 1) included age and sex. In addition to age and sex, Model 2 also included BSA, which is widely used for indexation of LV volumes, LV mass and cardiac output, to reduce variation related to body size (21, 23, 24). The ratio between the variance of the imaging biomarker and the variance of pSBP explained by gSBP (R^2) was determined using univariate linear regression analysis and reported. Interaction analyses were performed to test for the presence of interactions between gSBP, age and sex, using Model 2. Linear regression analyses were repeated in the validation cohort on all available imaging biomarkers. To compare results of gSBP with effects of the phenotype, linear regression analyses were repeated using pSBP as a continuous independent variable. Unstandardized effect sizes on imaging biomarkers were reported per 10 mmHg gSBP and pSBP. A Bonferroni correction was applied to reduce the chance of Type I error, a significance level of $0.05/9 = 0.0056$ was adopted as statistically significant. All aforementioned statistical analyses were conducted with STATA

version 15.1 (StataCorp LP, College Station, Texas, USA).

Mendelian randomization assumes that 1) the instrumental variable is associated with the risk factor of interest, 2) the instrumental variable is independent of confounders, and 3) the instrumental variable does not affect the outcome except through the risk factor. The first assumption was assessed by linear regression of pSBP against gSBP. The second assumption was assessed by adding baseline characteristics that were significantly different ($P < 0.05$) between study groups (possible confounders) to linear regression analyses. The third assumption was assessed by including pSBP as a covariate to linear regression analyses with gSBP.

If a significant effect of gSBP on a specific imaging parameter was observed after multivariable adjustment with Model 2, statistical tests were performed to assess the presence of pleiotropy or heterogeneity of the observed effect estimates. Individual SNP effect sizes on SBP were determined in all UK Biobank participants with available genetic information and no CMR assessment performed, using the same cutoff values for GRS as the study population (< 4.45 mmHg and > 13.16 mmHg). Individual SNP effect sizes on imaging parameters were determined using linear regression, corrected for confounders using Model 2, and visualized using Forest plots and scatter plots. Results from inverse-variance-weighted fixed-effects meta analyses of effect size on imaging parameters were reported. Mendelian randomization-Egger intercepts were determined, a P-value < 0.10 was considered evidence for pleiotropic bias. A Cochran's Q test was performed, a heterogeneity P-value < 0.05 was considered evidence for heterogeneity. Heterogeneity and pleiotropy tests were performed using the MR Base package (<https://mrcieu.github.io/TwoSampleMR/>) in R version 3.3.2.

RESULTS

Population characteristics

Baseline characteristics of the study population are presented in *Table 1*. The mean (SD) age of the study population was 62 (7) years and 52% of subjects were female. The difference in median gSBP between study groups was 10.34 mmHg, whereas the difference in mean pSBP between groups was 7.56 mmHg. The observed difference in mean pSBP was largely due to a difference in pulse pressure of 5.11 mmHg, and to a lesser extent due to a difference in DBP of 2.45 mmHg. The overlap in pSBP between study groups is displayed in *Figure 3*. In the high gSBP group, 47 subjects (31%) were diagnosed with hypertension, of which 41 (27%) used antihypertensive medication. In the low gSBP group, 26 subjects (17%) were diagnosed with hypertension, of which 18 (12%) used antihypertensive medication. Other significant baseline differences between

Table 1. Baseline characteristics

Characteristic	Low gSBP (N=150)	High gSBP (N=150)	P-value
Genetic risk score for systolic blood pressure (mmHg)	3.52 (2.85, 4.10)	13.86 (13.43, 14.45)	<0.001
Age (years)	61.31 (7.54)	62.13 (6.98)	0.33
Sex (male)	76 (50.7%)	69 (46.0%)	0.42
Townsend deprivation index at recruitment, inverse rank normalized	0.02 (0.94)	-0.27 (0.99)	0.010
Average total household income before tax			
<18,000	27 (19.6%)	13 (9.2%)	0.13
18,000-30,999	36 (26.1%)	37 (26.2%)	
31,000-51,999	32 (23.2%)	42 (29.8%)	
52,000-100,000	34 (24.6%)	36 (25.5%)	
>100,000	9 (6.5%)	13 (9.2%)	
Weight (kg)	72.30 (10.96)	71.83 (10.81)	0.71
Height (cm)	169.26 (8.77)	169.13 (8.82)	0.89
Body mass index (kg/m ²)	25.15 (2.64)	25.04 (2.68)	0.71
Body surface area (m ²)	1.83 (0.17)	1.82 (0.17)	0.76
Waist hip ratio	0.85 (0.08)	0.84 (0.07)	0.27
Systolic blood pressure (mmHg)	125.09 (16.57)	132.65 (15.94)	<0.001
Diastolic blood pressure (mmHg)	76.83 (8.15)	79.28 (8.12)	0.009
Pulse pressure (mmHg)	48.26 (11.90)	53.37 (12.20)	<0.001
Mean arterial pressure (mmHg)	92.92 (10.22)	97.07 (9.78)	<0.001
Total moderate physical activity (hrs/week)	6.35 (3.08, 14.38)	9.33 (3.71, 16.05)	0.033
Total vigorous physical activity (hrs/week)	1.38 (0.19, 3.50)	1.44 (0.38, 3.42)	0.33
Smoking behavior			
Non-smoker	78 (52.0%)	105 (70.0%)	0.008
Past smoker	62 (41.3%)	42 (28.0%)	
Active, occasional smoker	5 (3.3%)	2 (1.3%)	
Active, daily smoker	5 (3.3%)	1 (0.7%)	
Alcohol intake (UK Units/week)	9.60 (3.20, 16.10)	9.60 (3.20, 18.80)	0.88
Hypertension	26 (17.3%)	47 (31.3%)	0.005
Antihypertensive medication use	18 (12.0%)	41 (27.3%)	<0.001
Diabetes mellitus	5 (3.3%)	11 (7.3%)	0.12
Hyperlipidemia	27 (18.0%)	37 (24.7%)	0.16

gSBP, genetically predicted systolic blood pressure

groups not directly related to blood pressure were TDI ($P=0.010$), hours of moderate physical activity per week ($P=0.033$), and smoking status ($P=0.008$).


Mendelian randomization: effect of gSBP on LV structure and function

Inter- and intraobserver variability in determining imaging parameters was above 0.90 in all investigated parameters except LV mass to volume ratio and LV ejection fraction (*Supplementary Table S2*). Results from regression analyses with gSBP are presented in *Table 2*. We observed a significant ($P<0.0056$) association between gSBP and LV mass and LV global radial strain. Corrected for age, sex, and BSA, each 10 mmHg increase in gSBP was associated with 4.01 (SE 1.28, $P=0.002$) grams increase in LV mass and with 2.80 (SE 0.97, $P=0.004$) percent increase in LV global radial strain.

Mendelian randomization: testing assumptions

In our study population ($N=300$), gSBP was significantly associated with pSBP ($P<0.001$) and

Figure 3. Distribution of systolic blood pressure at imaging visit per study group



gSBP, genetically predicted systolic blood pressure

Table 2. Linear regression analyses of gSBP on imaging biomarkers (N=300)

Imaging biomarker	Univariate			Model 1		Model 2		R ² /R ² SBP
	B ± SE	P		B ± SE	P	B ± SE	P	
LV mass (g)	2.90 ± 2.01	0.15		4.37 ± 1.40	0.002	4.01 ± 1.28	0.002	0.16
LV end-diastolic volume (mL)	0.10 ± 3.59	0.98		2.74 ± 2.82	0.33	2.05 ± 2.62	0.44	0.00
LV end-systolic volume (mL)	-1.47 ± 2.06	0.47		-0.10 ± 1.70	0.95	-0.36 ± 1.66	0.83	0.03
LV mass to end-diastolic volume ratio	0.0177 ± 0.0094	0.060		0.0194 ± 0.0087	0.025	0.0191 ± 0.0087	0.028	0.27
LV cardiac output (L/min)	0.04 ± 0.13	0.78		0.12 ± 0.11	0.29	0.10 ± 0.11	0.37	0.01
LV ejection fraction (%)	1.00 ± 0.66	0.13		0.81 ± 0.64	0.21	0.79 ± 0.65	0.22	0.14
LV peak global circumferential strain (%)	-0.79 ± 0.28	0.005		-0.66 ± 0.27	0.014	-0.66 ± 0.27	0.014	0.49
LV peak global radial strain (%)	3.24 ± 1.02	0.002		2.80 ± 0.97	0.004	2.81 ± 0.97	0.004	0.62
LV peak global longitudinal strain (%)	-0.03 ± 0.25	0.91		-0.06 ± 0.25	0.80	-0.06 ± 0.25	0.82	0.00

gSBP, genetically predicted systolic blood pressure; LV, left ventricular

Reported are unstandardized coefficients and standard errors per 10 mmHg increase of genetically predicted systolic blood pressure (genetic risk score). Model 1 consists of covariates age and sex. Model 2 consists of covariates age, sex, and body surface area. All analyses are adjusted for the genotyping chip used and the first five principal components.

Table 3. Replication of gSBP effect size in previously determined imaging biomarkers by Petersen et al. (N=2,530)

Imaging biomarker	Univariate			Model 1			Model 2			R ² /R ² SBP
	B ± SE	P		B ± SE	P		B ± SE	P		
LV mass (g)	7.14 ± 2.25	0.001		5.90 ± 1.63	<0.001		5.27 ± 1.50	<0.001		0.29
LV end-diastolic volume (mL)	7.54 ± 3.23	0.020		5.75 ± 2.56	0.025		4.82 ± 2.38	0.043		0.15
LV end-systolic volume (mL)	4.75 ± 1.82	0.009		3.84 ± 1.54	0.013		3.42 ± 1.48	0.021		0.18
LV mass to end-diastolic volume ratio	0.0157 ± 0.0110	0.15		0.0146 ± 0.0105	0.16		0.0140 ± 0.0105	0.18		0.06
LV cardiac output (L/min)	0.11 ± 0.11	0.34		0.07 ± 0.10	0.47		0.04 ± 0.10	0.66		0.03
LV ejection fraction (%)	-0.70 ± 0.59	0.24		-0.59 ± 0.58	0.31		-0.57 ± 0.58	0.33		0.03

gSBP, genetically predicted systolic blood pressure; LV, left ventricular

Reported are unstandardized coefficients and standard errors per 10 mmHg increase of genetically predicted systolic blood pressure (genetic risk score). Model 1 consists of covariates age and sex. Model 2 consists of covariates age, sex, and body surface area. All analyses are adjusted for the genotyping chip used and the first five principal components.

explained 5.5% of its variance. Adding baseline characteristics that were significantly different ($P<0.05$) between study groups (TDI, moderate physical activity, smoking status) to linear regression analyses did not change the observed effect of gSBP on LV mass and global radial strain from significant to nonsignificant. Adding pSBP to linear regression analyses changed the associations between gSBP and both LV mass and LV global radial strain from significant to nonsignificant ($P=0.10$ and $P=0.030$ respectively).

Mendelian randomization: pleiotropy and heterogeneity

Pleiotropy and heterogeneity analyses were performed for observed associations between gSBP and LV mass, and LV peak global radial strain. Forest plots and scatter plots with meta-analyzed results are presented in *Supplementary Figure S2* and *Supplementary Figure S3* respectively. Results from inverse-variance-weighted fixed-effects meta analyses, Mendelian randomization-Egger intercepts and heterogeneity P-values from Cochran's Q test are presented in *Supplementary Table S3*. There was no evidence for pleiotropic bias or heterogeneity in any of the investigated associations.

Interactions between gSBP, age and sex

There was a significant interaction between gSBP and age on LV global radial strain ($P=0.031$), suggesting a difference in effect of gSBP on radial strain with varying age. An additional interaction was observed between gSBP and sex on LVESV ($P=0.030$), suggesting a reduction of LVESV with increasing gSBP in males, but not in females.

Validation using previously derived imaging parameters

We attempted to validate the observed results by repeating linear regression analyses with gSBP on LV mass, volumes, mass to volume ratio, cardiac output and ejection fraction in 2,530 independent subjects with previously derived imaging parameters (*Table 3*). As in the study cohort, we observed a significant ($P<0.0056$) association between gSBP and LV mass in the validation cohort, all other associations were nonsignificant. Corrected for age, sex, and BSA, a 10 mmHg increase in gSBP was associated with an increase of 5.27 (SE 1.50, $P<0.001$) grams in LV mass. The interaction between gSBP and sex on LVESV could not be reproduced in the validation cohort ($P>0.05$). LV myocardial strain measures were not available in the validation cohort.

Discrepancies with phenotype associations

Results from regression analyses of pSBP are reported in *Supplementary Table S4*. Corrected for age, sex, and BSA, we observed significant associations ($P<0.0056$) between pSBP and LV mass ($\beta = 2.87 \pm 0.46$ g/10 mmHg, $P<0.001$), and LV global radial strain ($\beta = 1.07 \pm 0.37$ %/10 mmHg, $P=0.004$). Associations that were significant for the phenotype but not for the genotype were associations between pSBP and LV mass to volume ratio ($\beta = 0.0138 \pm 0.0032$ /10 mmHg,

$P < 0.001$), and cardiac output ($\beta = 0.20 \pm 0.04 \text{ L/10 mmHg}$, $P < 0.001$).

DISCUSSION

We investigated CMR-derived measures of LV structure and function in 300 individuals with extremes of gSBP. The main findings of our study were observed associations between gSBP and increased LV mass and LV global radial strain, providing evidence for a causal relationship between gSBP and adverse LV remodeling.

Hypertension does generally not lead to symptoms, meaning that individuals who are affected often do not visit a medical professional until a symptomatic comorbidity such as myocardial ischemia due to coronary artery disease has manifested. Hypertension is the leading risk factor for deaths due to cardiovascular diseases, causing more than 40% of cardiovascular deaths (25). Even small increases in blood pressure from thresholds of 115 mmHg SBP and 75 mmHg DBP have been associated with an increased risk of cardiovascular events (26). Therefore, more recently, the American Heart Association's 2017 guideline has suggested lower thresholds for stage 1 hypertension at SBP values between 130-139 mmHg and/or DBP values between 80-89 mmHg (2). The association between raised SBP and increased risk of cardiovascular disease has been shown repeatedly (1, 2), resulting in its inclusion in commonly used prediction models such as the Framingham risk score (27).

MR analyses using GRSs can provide evidence for causal relationships. This is especially valuable in studying processes with a multifactorial etiology such as LV remodeling. gSBP has been previously associated with increased risk of cardiovascular diseases such as coronary heart disease, atrial fibrillation, and stroke (10, 13, 28). To our knowledge, the present study is the first to report the association between gSBP and changes in CMR-derived measurements of LV structure and function. The current study provides evidence for a causal relationship between SBP and adverse LV remodeling. We observed a large effect of gSBP on LV mass. These findings are in line with an earlier study that showed a significant association between gSBP using 29 genetic variants and increased LV wall thickness as measured by echocardiography (29). Similar associations for pSBP have been reported before (30). LV mass and concentricity are known to be strong predictors of incident cardiovascular events (31). Although confidence intervals somewhat overlapped, point estimates of the effect size of gSBP were larger compared with pSBP. The observed effect sizes are likely underestimated, because the GRS for SBP was based on the estimated effect size of SBP-raising genetic variants, and differences in GRS between groups were larger than differences in measured SBP. Larger effects of gSBP on LV mass compared to pSBP is an expected result,

as pSBP is a snapshot at a specific moment in time, affected by many confounding factors (such as “white coat hypertension”), whereas gSBP is stable and its effects are cumulative over a whole lifetime.

We observed a strong association between gSBP and increased LV radial strain, which was also observed for pSBP, but to a much lesser extent. Previous studies have mostly reported associations between hypertension and impaired LV longitudinal strain, and in some cases also impaired circumferential strain (32, 33). Other studies observed that LV myocardial strain is most significantly impaired in subjects with both obesity and hypertension (34), and we investigated a population free of obesity. As a prolonged exposure to high blood pressure can eventually progress into heart failure, we suspect that these studies have investigated individuals that had already suffered hypertension-related injury to the myocardium. We hypothesize that in a general population, blood pressure is associated with increased LV contractility and myocardial strain, whereas in more severe stages of hypertension, it is associated with strain impairment.

Future perspectives

Our study indicates that gSBP is strongly related to increased LV mass, and radial strain indicating that long-term exposure to higher blood pressure directly impacts cardiac structure and function. Future studies will have to reveal whether a genetically predicted risk of hypertension also has additional value in predicting and preventing cardiovascular risk. GRSs are a potential detection tool that can be used for the prevention of cardiovascular disease starting from an early stage in life. Because genetic variants are present from conception, they will have a cumulative burden on the cardiovascular system during one’s lifetime. However, not only genetic composition but also lifestyle is strongly associated with risk of developing hypertension and future (cardiovascular) events (19). The effect of lifestyle on cardiovascular disease, as well as the effect of lifestyle on pSBP are independent from the effects of gSBP (19, 35). Risk stratification based on genetic composition as well as lifestyle might eventually lead to clinical trial designs where individuals at high genetic risk receive early antihypertensive lifestyle or pharmacologic interventions. Future studies could aim at determining whether hypertensive individuals with a large genetic component respond differently to pharmacologic treatment.

Strengths and limitations

This study is the first to perform Mendelian randomization analyses of SBP on CMR-derived imaging biomarkers of LV structure and function. Major strengths of this study were the use of CMR data, balanced GRS-based groups, and the comparison between genotype and phenotype. A limitation of our study that should be considered is that we investigated subjects with extreme GRS values and therefore did not cover the full range as is usually done in MR analyses. We

were however able to validate some of our results in a large subset of UK Biobank participants with previously derived imaging parameters and a normal distribution of genetic risk. A second limitation is that we have selected a relatively healthy population, free of obesity, and therefore our results might not be generalizable.

Perspectives

By investigating associations between genetically predicted higher SBP and imaging parameters derived from CMR, our study provides evidence supporting a causal relationship between SBP and increased LV mass and increased LV global radial strain. These results further improve our understanding of pathophysiology in hypertensive heart disease. As more genetic variants related to blood pressure are being discovered, genetic variants more strongly associated with adverse cardiac remodeling such as concentric hypertrophy could provide potential targets for therapy.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 12010. We thank Ruben N. Eppinga, MD, M. Yldau van der Ende, BSc, Yordi J. van de Vegte, BSc, Yanick Hagemeijer, MSc, and Jan-Walter Benjamins, BEng, University of Groningen, University Medical Center Groningen, Department of Cardiology, for their contributions to the extraction and processing of data in the UK Biobank. None of the mentioned contributors received compensation, except for their employment at the University Medical Center Groningen.

Source(s) of Funding

This work was supported by the Netherlands Heart Foundation (grant 2018B017). The funder had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.

Disclosures

None.

Supplementary Table S1. Single Nucleotide Polymorphisms used to build genetic risk score of systolic blood pressure.

SNP rsID	Chr.	hg19 position	NEPAL	EFAL	EF Frequency	Beta	SE	P value	Study year (PMID)	Comment
rs880315	1	10796866	C	T	0.641	-0.475	0.062	2.09E-14	Ehret et al. 2016 (27618452)	
rs17037390	1	11860843	G	A	0.155	-0.908	0.081	5.95E-29	Ehret et al. 2016 (27618452)	
rs7515635	1	42408070	C	T	0.468	0.336	0.057	4.54E-09	Ehret et al. 2016 (27618452)	Removed
rs1620668	1	113023980	G	A	0.822	-0.535	0.076	1.45E-12	Ehret et al. 2016 (27618452)	
rs2493134	1	230849359	C	T	0.579	-0.413	0.058	9.65E-13	Ehret et al. 2016 (27618452)	
rs2586886	2	26932031	C	T	0.599	-0.404	0.059	5.94E-12	Ehret et al. 2016 (27618452)	
rs1371182	2	165099215	C	T	0.443	-0.444	0.058	1.89E-14	Ehret et al. 2016 (27618452)	
rs2594992	3	11360997	C	A	0.607	-0.334	0.06	2.31E-08	Ehret et al. 2016 (27618452)	
rs11128722	3	14958126	G	A	0.563	-0.383	0.061	4.44E-10	Ehret et al. 2016 (27618452)	
rs711737	3	27543655	C	A	0.604	0.334	0.058	9.93E-09	Ehret et al. 2016 (27618452)	
rs6442101	3	48130893	C	T	0.692	0.396	0.062	1.62E-10	Ehret et al. 2016 (27618452)	
rs6779380	3	169111915	C	T	0.539	-0.439	0.06	1.85E-13	Ehret et al. 2016 (27618452)	
rs2291435	4	38387395	C	T	0.524	-0.378	0.059	1.03E-10	Ehret et al. 2016 (27618452)	
rs1458038	4	81164723	C	T	0.3	0.659	0.065	5.36E-24	Ehret et al. 2016 (27618452)	
rs17010957	4	86719165	C	T	0.857	-0.498	0.082	1.51E-09	Ehret et al. 2016 (27618452)	Removed
rs13107325	4	103188709	C	T	0.07	-0.837	0.127	4.69E-11	Ehret et al. 2016 (27618452)	
rs4691707	4	156441314	G	A	0.652	-0.349	0.06	7.10E-09	Ehret et al. 2016 (27618452)	
rs12656497	5	32831939	C	T	0.403	-0.487	0.06	3.85E-16	Ehret et al. 2016 (27618452)	
rs10077885	5	114390121	C	A	0.501	-0.261	0.058	5.50E-06	Ehret et al. 2016 (27618452)	Removed
rs11953630	5	157845402	C	T	0.366	-0.38	0.065	3.91E-09	Ehret et al. 2016 (27618452)	Removed
rs1799945	6	26091179	G	C	0.857	-0.598	0.086	3.28E-12	Ehret et al. 2016 (27618452)	
rs6919440	6	43352898	G	A	0.57	-0.337	0.058	4.92E-09	Ehret et al. 2016 (27618452)	Removed
rs1361831	6	127181089	C	T	0.541	-0.482	0.058	7.38E-17	Ehret et al. 2016 (27618452)	
rs2969070	7	2512545	G	A	0.639	-0.315	0.061	1.93E-07	Ehret et al. 2016 (27618452)	
rs3735533	7	27245893	C	T	0.081	-0.798	0.106	6.48E-14	Ehret et al. 2016 (27618452)	
rs12705390	7	106410777	G	A	0.227	0.619	0.069	2.69E-19	Ehret et al. 2016 (27618452)	
rs11556924	7	129663496	C	T	0.384	-0.336	0.062	6.05E-08	Ehret et al. 2016 (27618452)	
rs2898290	8	11433909	C	T	0.491	0.377	0.058	8.85E-11	Ehret et al. 2016 (27618452)	
rs10760117	9	123586737	G	T	0.415	0.334	0.06	2.54E-08	Ehret et al. 2016 (27618452)	
rs6271	9	136322274	C	T	0.072	-0.567	0.122	3.60E-06	Ehret et al. 2016 (27618452)	
rs12243859	10	18740632	C	T	0.326	-0.402	0.061	6.13E-11	Ehret et al. 2016 (27618452)	
rs7076398	10	63533663	T	A	0.188	-0.563	0.076	1.72E-13	Ehret et al. 2016 (27618452)	

SNP rsID	Chr.	hg19 position	NEPAL	EFAL	EF Frequency	Beta	SE	P value	Study year (PMID)	Comment
rs12247028	10	75410052	G	A	0.611	-0.364	0.063	8.16E-09	Ehret et al. 2016 (27618452)	
rs932764	10	98505940	G	A	0.554	-0.495	0.059	6.88E-17	Ehret et al. 2016 (27618452)	
rs943037	10	104835919	C	T	0.087	-1.133	0.105	2.35E-27	Ehret et al. 2016 (27618452)	
rs740746	10	115792787	G	A	0.73	0.486	0.067	4.59E-13	Ehret et al. 2016 (27618452)	
rs592373	11	1890990	G	A	0.64	0.484	0.063	2.02E-14	Ehret et al. 2016 (27618452)	
rs1450271	11	10356115	C	T	0.468	0.413	0.059	3.40E-12	Ehret et al. 2016 (27618452)	
rs1156725	11	16307700	C	T	0.804	-0.447	0.072	5.65E-10	Ehret et al. 2016 (27618452)	
rs7103648	11	47461783	G	A	0.614	-0.267	0.061	1.09E-05	Ehret et al. 2016 (27618452)	Removed
rs751984	11	61278246	C	T	0.879	0.341	0.088	1.11E-04	Ehret et al. 2016 (27618452)	
rs3741378	11	65408937	C	T	0.137	-0.486	0.084	8.04E-09	Ehret et al. 2016 (27618452)	
rs633185	11	100593538	G	C	0.715	0.522	0.067	6.97E-15	Ehret et al. 2016 (27618452)	
rs11105354	12	90026323	G	A	0.84	0.909	0.081	3.88E-29	Ehret et al. 2016 (27618452)	
rs3184504	12	111884608	C	T	0.475	0.498	0.062	9.97E-16	Ehret et al. 2016 (27618452)	
rs936226	15	75069282	C	T	0.722	-0.549	0.067	3.06E-16	Ehret et al. 2016 (27618452)	
rs2521501	15	91437388	T	A	0.684	-0.639	0.069	3.35E-20	Ehret et al. 2016 (27618452)	
rs7213273	17	43155914	G	A	0.658	-0.413	0.066	4.71E-10	Ehret et al. 2016 (27618452)	
rs17068766	17	45013271	C	T	0.854	-0.658	0.083	2.27E-15	Ehret et al. 2016 (27618452)	
rs12958173	18	42141977	C	A	0.306	0.386	0.063	1.19E-09	Ehret et al. 2016 (27618452)	Removed
rs4247374	19	7252756	C	T	0.143	-0.446	0.091	1.05E-06	Ehret et al. 2016 (27618452)	Removed
rs1327235	20	10969030	G	A	0.542	-0.395	0.059	2.23E-11	Ehret et al. 2016 (27618452)	
rs6026748	20	57745815	G	A	0.125	0.867	0.089	3.15E-22	Ehret et al. 2016 (27618452)	
rs12627651	21	44760603	G	A	0.288	0.503	0.068	1.97E-13	Ehret et al. 2016 (27618452)	
rs783621	1	42368035	G	A	NA	0.329	NA	4.20E-12	Hoffman et al. 2017 (27841878)	
rs2404715	1	57008778	T	C	NA	0.313	NA	1.60E-04	Hoffman et al. 2017 (27841878)	
rs60199046	1	59663341	G	A	NA	0.165	NA	2.50E-03	Hoffman et al. 2017 (27841878)	
rs2761436	1	207919748	T	C	NA	-0.279	NA	8.40E-09	Hoffman et al. 2017 (27841878)	
rs13403122	2	43078758	T	C	NA	0.29	NA	1.20E-07	Hoffman et al. 2017 (27841878)	
rs6434404	2	191494411	G	A	NA	0.346	NA	2.90E-10	Hoffman et al. 2017 (27841878)	
rs1250247	2	216299629	G	C	NA	0.252	NA	4.30E-06	Hoffman et al. 2017 (27841878)	
rs12630213	3	14954411	T	C	NA	0.307	NA	8.70E-10	Hoffman et al. 2017 (27841878)	Removed
rs75305034	3	133866705	C	T	NA	0.331	NA	3.40E-10	Hoffman et al. 2017 (27841878)	
rs2178452	3	160370160	A	G	NA	0.304	NA	1.30E-09	Hoffman et al. 2017 (27841878)	
rs13104866	4	38402183	A	G	NA	0.292	NA	1.20E-09	Hoffman et al. 2017 (27841878)	Removed

SNP rsID	Chr.	hg19 position	NEPAL	EFAL	EP Frequency	Beta	SE	P value	Study year (PMID)	Comment
rs4292285	4	145271954	A	T	NA	0.25	NA	2.30E-07	Hoffman et al. 2017 (27841878)	
rs4473250	5	114375552	A	G	NA	0.297	NA	5.30E-10	Hoffman et al. 2017 (27841878)	
rs35410524	6	90885405	T	C	NA	-0.359	NA	4.00E-09	Hoffman et al. 2017 (27841878)	
rs10818775	9	125755571	T	C	NA	0.333	NA	1.50E-06	Hoffman et al. 2017 (27841878)	
rs34872471	10	114754071	C	T	NA	-0.257	NA	1.40E-06	Hoffman et al. 2017 (27841878)	
rs360158	11	9753601	A	G	NA	-0.291	NA	2.90E-09	Hoffman et al. 2017 (27841878)	Removed
rs7107356	11	47676170	G	A	NA	-0.281	NA	3.50E-09	Hoffman et al. 2017 (27841878)	
rs61448762	11	48923756	A	G	NA	0.439	NA	2.10E-08	Hoffman et al. 2017 (27841878)	Removed
rs7927515	11	76125330	A	C	NA	-0.249	NA	6.50E-07	Hoffman et al. 2017 (27841878)	
rs2289125	11	89224453	C	A	NA	-0.207	NA	2.30E-04	Hoffman et al. 2017 (27841878)	
rs7973789	12	49981722	C	T	NA	0.322	NA	2.00E-05	Hoffman et al. 2017 (27841878)	
rs10747570	12	50509937	G	A	NA	0.302	NA	1.40E-09	Hoffman et al. 2017 (27841878)	
rs63418562	13	30146201	T	C	NA	0.312	NA	8.90E-09	Hoffman et al. 2017 (27841878)	
rs3011549	13	113634937	C	A	NA	0.347	NA	3.90E-08	Hoffman et al. 2017 (27841878)	
rs2759308	15	81016227	A	G	NA	-0.302	NA	6.90E-10	Hoffman et al. 2017 (27841878)	
rs12596053	16	4946794	C	A	NA	-0.318	NA	7.40E-11	Hoffman et al. 2017 (27841878)	
rs35261357	16	75444572	T	C	NA	-0.184	NA	1.50E-04	Hoffman et al. 2017 (27841878)	
rs460105	16	89682006	C	T	NA	0.327	NA	8.10E-09	Hoffman et al. 2017 (27841878)	
rs12606620	18	42008097	T	G	NA	0.319	NA	5.20E-10	Hoffman et al. 2017 (27841878)	
rs2193635	18	43096236	T	C	NA	-0.269	NA	6.70E-06	Hoffman et al. 2017 (27841878)	
rs10427021	19	7259346	G	T	NA	0.375	NA	1.60E-07	Hoffman et al. 2017 (27841878)	
rs8105753	19	31927547	C	A	NA	0.298	NA	1.60E-09	Hoffman et al. 2017 (27841878)	
rs141216986	23	127728549	T	C	NA	0.818	NA	1.70E-08	Hoffman et al. 2017 (27841878)	Removed
rs2014912	4	86715670	C	T	0.165	0.620	0.074	5.37E-17	Kato et al. 2015 (26390057)	
rs13359291	5	122476457	G	A	0.273	0.534	0.066	8.88E-16	Kato et al. 2015 (26390057)	
rs1563788	6	43308363	C	T	0.309	0.511	0.062	2.22E-16	Kato et al. 2015 (26390057)	
rs2493292	1	3328659	C	T	0.151	0.37	0.07	1.40E-08	Liu et al. 2016 (27618448)	
rs2270860	6	43270151	C	T	0.367	0.32	0.05	2.90E-11	Liu et al. 2016 (27618448)	Removed
rs5219	11	17409572	C	T	0.32	0.32	0.05	4.90E-12	Liu et al. 2016 (27618448)	
rs11639856	16	24788645	T	A	0.193	-0.34	0.06	1.30E-08	Liu et al. 2016 (27618448)	
rs4823006	22	29451671	A	G	0.424	-0.26	0.05	7.90E-09	Liu et al. 2016 (27618448)	
rs35529250	4	40428091	C	T	0.0097	-15.511	NA	2.42E-08	Surendran et al. 2016 (27618447)	
rs1008058	5	122435627	G	A	0.1325	0.5535	NA	2.99E-10	Surendran et al. 2016 (27618447)	Removed

SNP rsID	Chr.	hg19 position	NEPAL	EFAL	EF Frequency	Beta	SE	P value	Study year (PMID)	Comment
rs9349379	6	12903957	G	A	0.5686	0.289	NA	8.84E-10	Surendran et al. 2016 (27618447)	
rs4728142	7	128573967	G	A	0.4341	-0.2416	NA	3.45E-08	Surendran et al. 2016 (27618447)	
rs34591516	8	142367087	C	T	0.0539	0.6358	NA	6.10E-10	Surendran et al. 2016 (27618447)	
rs4387287	10	105677897	C	A	0.1556	0.361	NA	9.12E-10	Surendran et al. 2016 (27618447)	
rs11229457	11	58207203	C	T	0.2332	-0.312	NA	2.70E-08	Surendran et al. 2016 (27618447)	
rs7406910	17	46688256	C	T	0.1136	-0.4563	NA	3.80E-08	Surendran et al. 2016 (27618447)	
rs139385870	1	1685921	TCCCTGGACCGAAGTTCGCCCA	T	NA	-0.31	0.07	1.00E-05	Warren et al. 2017 (28135244)	Missing in UK Bio
rs3820068	1	15798197	G	A	NA	0.367	0.08	5.50E-06	Warren et al. 2017 (28135244)	
rs10922502	1	89360158	G	A	NA	-0.307	0.06	2.00E-06	Warren et al. 2017 (28135244)	
rs7562	2	28635740	C	T	NA	0.182	0.06	3.70E-03	Warren et al. 2017 (28135244)	
rs13420463	2	37517566	G	A	NA	0.244	0.07	7.30E-04	Warren et al. 2017 (28135244)	
rs55780018	2	208326140	C	T	NA	-0.36	0.07	5.10E-08	Warren et al. 2017 (28135244)	
rs9859176	3	134000025	C	T	NA	0.248	0.06	9.60E-05	Warren et al. 2017 (28135244)	Removed
rs13112725	4	106911742	G	C	NA	0.45	0.08	9.40E-09	Warren et al. 2017 (28135244)	
rs10059921	5	87514515	G	T	NA	-0.417	0.12	7.90E-04	Warren et al. 2017 (28135244)	
rs6595838	5	127868199	G	A	NA	0.236	0.07	4.50E-04	Warren et al. 2017 (28135244)	
rs6911827	6	22130601	C	T	NA	0.19	0.06	2.10E-03	Warren et al. 2017 (28135244)	
rs78648104	6	50683009	C	T	NA	-0.329	0.11	4.00E-03	Warren et al. 2017 (28135244)	
rs13238550	7	131059036	G	A	NA	0.212	0.06	7.10E-04	Warren et al. 2017 (28135244)	
rs1011018	7	139463264	G	A	NA	-0.244	0.08	1.60E-03	Warren et al. 2017 (28135244)	Missing in UK B
rs894344	8	135612745	G	A	NA	-0.163	0.06	8.20E-03	Warren et al. 2017 (28135244)	
rs112184198	10	102604514	G	A	NA	-0.532	0.1	1.30E-07	Warren et al. 2017 (28135244)	
rs6487543	12	26438189	G	A	NA	0.279	0.06	2.10E-06	Warren et al. 2017 (28135244)	
rs9549328	13	113636156	C	T	NA	0.218	0.08	3.90E-03	Warren et al. 2017 (28135244)	Removed
rs9888615	14	53377540	C	T	NA	-0.236	0.07	4.30E-04	Warren et al. 2017 (28135244)	
rs8016306	14	63928546	G	A	NA	0.25	0.07	7.90E-04	Warren et al. 2017 (28135244)	
rs35199222	15	81013037	G	A	NA	0.298	0.06	1.70E-06	Warren et al. 2017 (28135244)	Removed
rs11643209	16	75331044	G	T	NA	-0.222	0.06	6.30E-04	Warren et al. 2017 (28135244)	Removed
rs12941318	17	1333598	C	T	NA	-0.226	0.07	6.90E-04	Warren et al. 2017 (28135244)	
rs2467099	17	73949045	C	T	NA	-0.216	0.07	3.60E-03	Warren et al. 2017 (28135244)	

For Single Nucleotide Polymorphisms (SNPs) found by Ehret et al. the Beta, standard error and P value from the Stage 4 meta-analysis for the novel loci, rather than the results that include UK Biobank data were used. For SNPs found by Hoffman et al. we used betas, standard error and P value from the GRA+ICBP cohort if the SNP had a P value < 5E-8. For SNPs found by Warren et al. we used the Beta, standard error and P values that did not include UK Biobank data, but which were found in the combined GWAS with a P value < 5E-8. SNPs found by Hoffman et al., Surendran et al., Kato et al., and Liu et al. include SNPs from analyses that included both European and non-European populations.

Supplementary Table S2. Intra- and interobserver variability

Imaging biomarker	Intraobserver variability	Interobserver variability
LV mass	0.93	0.91
LV end-diastolic volume	0.96	0.98
LV end-systolic volume	0.96	0.96
LV mass to end-diastolic volume ratio	0.52	0.73
LV cardiac output	0.94	0.94
LV ejection fraction	0.91	0.80
LV peak global circumferential strain	0.91	0.94
LV peak global radial strain	0.84	0.96
LV peak global longitudinal strain	0.98	0.88

LV, left ventricular


Supplementary Table S3. Pleiotropy and heterogeneity tests

Imaging biomarker	Inverse-variance-weighted estimate		MR Egger		Heterogeneity	
	Beta ± SE	P-value	Intercept ± SE	P-value	P-value	P-value
LV mass	4.69 ± 0.84	<0.001	-0.13 ± 0.33	0.71		0.17
LV peak global radial strain	3.84 ± 0.63	<0.001	-0.15 ± 0.25	0.55		0.12


MR, Mendelian randomization; LV, left ventricular

Inverse-variance-weighted estimates are reported per 10 mmHg


Supplementary Figure S1. Post-processing CMR feature tracking analyses.



Supplementary Figure S2. Forest plots. Effect sizes of individual SNPs and meta-analyzed results on A) LV mass and B) global radial strain.



Supplementary Figure S3. Scatter plots. Effect size of SNPs on systolic blood pressure plotted against effect size of SNPs on A) LV mass and B) global radial strain.



REFERENCES

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013 Jul;34(28):2159-219.
2. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018 May 15;71(19):e127-248.
3. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. *Circulation*. 2018 Jan 9;137(2):109-18.
4. Garg S, de Lemos JA, Ayers C, Khouri MG, Pandey A, Berry JD, et al. Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population. *JACC Cardiovasc Imaging*. 2015 Sep;8(9):1034-41.
5. Velagaleti RS, Gona P, Pencina MJ, Aragam J, Wang TJ, Levy D, et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. *Am J Cardiol*. 2014 Jan 1;113(1):117-22.
6. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. *J Am Coll Cardiol*. 2004 Jun 16;43(12):2207-15.
7. Ehret GB, Ferreira T, Chasman DI, Jackson AU, Schmidt EM, Johnson T, et al. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nat Genet*. 2016 Oct;48(10):1171-84.
8. Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok PY, et al. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. *Nat Genet*. 2017 Jan;49(1):54-64.
9. Surendran P, Drenos F, Young R, Warren H, Cook JP, Manning AK, et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet*. 2016 Oct;48(10):1151-61.
10. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet*. 2017 Mar;49(3):403-15.
11. Liu C, Kraja AT, Smith JA, Brody JA, Franceschini N, Bis JC, et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. *Nat Genet*. 2016 Oct;48(10):1162-70.
12. Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. *Nat Genet*. 2015 Nov;47(11):1282-93.
13. Lieb W, Jansen H, Loley C, Pencina MJ, Nelson CP, Newton-Cheh C, et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. *Hypertension*. 2013 May;61(5):995-1001.
14. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, et al. UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson*. 2016 Feb 1;18:8,016-0227-4.

15. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv*. 2017 Cold Spring Harbor Laboratory Press.
16. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. *Nutrition*. 1989 Sep-Oct;5(5):303,11; discussion 312-3.
17. Stang A, Moebus S, Mohlenkamp S, Dragano N, Schmermund A, Beck EM, et al. Algorithms for converting random-zero to automated oscillometric blood pressure values, and vice versa. *Am J Epidemiol*. 2006 Jul 1;164(1):85-94.
18. 2008 physical activity guidelines for Americans [Internet].; 2008 []. Available from: <https://health.gov/paguidelines/2008/>.
19. Said MA, Verweij N, van der Harst P. Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study. *JAMA Cardiol*. 2018 Jun 27.
20. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. *J Cardiovasc Magn Reson*. 2013 May 1;15:35,429X-15-35.
21. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. *J Cardiovasc Magn Reson*. 2017 Feb 3;19(1):18,017-0327-9.
22. Petersen SE, Sanghvi MM, Aung N, Cooper JA, Paiva JM, Zemrak F, et al. The impact of cardiovascular risk factors on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. *PLoS One*. 2017 Oct 3;12(10):e0185114.
23. Le Ven F, Bibeau K, De Larochelliere E, Tizon-Marcos H, Deneault-Bissonnette S, Pibarot P, et al. Cardiac morphology and function reference values derived from a large subset of healthy young Caucasian adults by magnetic resonance imaging. *Eur Heart J Cardiovasc Imaging*. 2015 Sep 9.
24. Chuang ML, Gona P, Hautvast GL, Salton CJ, Breeuwer M, O'Donnell CJ, et al. CMR reference values for left ventricular volumes, mass, and ejection fraction using computer-aided analysis: the Framingham Heart Study. *J Magn Reson Imaging*. 2014 Apr;39(4):895-900.
25. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. *Lancet Diabetes Endocrinol*. 2014 Aug;2(8):634-47.
26. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002 Dec 14;360(9349):1903-13.
27. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998 May 12;97(18):1837-47.
28. He L, Culminkaya I, Loika Y, Arbeev KG, Bagley O, Duan M, et al. Causal effects of cardiovascular risk factors on onset of major age-related diseases: A time-to-event Mendelian randomization study. *Exp Gerontol*. 2018 Jul 1;107:74-86.
29. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*. 2011 Sep 11;478(7367):103-9.
30. Lieb W, Gona P, Larson MG, Aragam J, Zile MR, Cheng S, et al. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. *JACC Cardiovasc Imaging*. 2014 Sep;7(9):870-8.

31. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol*. 2008 Dec 16;52(25):2148-55.
32. Tadic M, Cuspidi C, Celic V, Ivanovic B, Pencic B, Grassi G. The influence of sex on left ventricular strain in hypertensive population. *J Hypertens*. 2019 Jan;37(1):50-6.
33. Fung MJ, Thomas L, Leung DY. Left ventricular function and contractile reserve in patients with hypertension. *Eur Heart J Cardiovasc Imaging*. 2018 Nov 1;19(11):1253-9.
34. Tadic M, Cuspidi C, Pencic B, Andric A, Pavlovic SU, Iracek O, et al. The interaction between blood pressure variability, obesity, and left ventricular mechanics: findings from the hypertensive population. *J Hypertens*. 2016 Apr;34(4):772-80.
35. Pazoki R, Dehghan A, Evangelou E, Warren H, Gao H, Caulfield M, et al. Genetic Predisposition to High Blood Pressure and Lifestyle Factors: Associations With Midlife Blood Pressure Levels and Cardiovascular Events. *Circulation*. 2018 Feb 13;137(7):653-61.

PART II: MYOCARDIAL INFARCTION

